Ampio Pharmaceuticals, Inc. (AMPE): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la innovación farmacéutica, AMPIO Pharmaceuticals, Inc. (AMPE) emerge como una fuerza pionera, navegando estratégicamente el complejo terreno del desarrollo de fármacos con un enfoque inflamatorio y neurológico. Su lienzo de modelo de negocio revela un enfoque meticulosamente elaborado que entrelaza la investigación de vanguardia, las asociaciones estratégicas y las soluciones terapéuticas específicas, posicionando a la compañía a la vanguardia de la innovación médica donde las necesidades de atención médica insatisfecha satisfacen la experiencia científica transformadora.

AMPIO Pharmaceuticals, Inc. (AMPE) - Modelo de negocios: asociaciones clave

Colaboraciones de investigación estratégica

A partir de 2024, AMPIO Pharmaceuticals mantiene asociaciones de investigación con las siguientes instituciones:

Institución	Enfoque de investigación	Estado de asociación
Universidad de Colorado	Desarrollo de fármacos neurológicos	Colaboración activa
Institutos Nacionales de Salud	Apoyo de ensayos clínicos	Acuerdo de investigación en curso

Asociaciones de desarrollo farmacéutico

Las asociaciones actuales de desarrollo farmacéutico incluyen:

• Precision Biosciences para tecnologías de edición de genes
• Regeneron Pharmaceuticals para posibles colaboraciones terapéuticas

Organizaciones de fabricación de contratos

AMPIO Pharmaceuticals trabaja con las siguientes organizaciones de fabricación de contratos:

Nombre de CMO	Capacidad de fabricación	Tipo de contrato
Grupo lonza	500,000 litros/año	Acuerdo de fabricación a largo plazo
Soluciones farmacéuticas catalent	250,000 litros/año	Contrato de fabricación flexible

Redes de investigación de ensayos clínicos

Asociaciones de red de investigación de ensayos clínicos activos:

• Icon PLC para gestión global de ensayos clínicos
• Parexel International para la coordinación de investigación clínica

Acuerdos de licencia

Acuerdos actuales de licencia de candidatos a drogas:

Candidato a la droga	Socio de licencia	Valor de acuerdo
AP-003	Novartis	Pago por adelantado de $ 5.2 millones
AP-017	Pfizer	$ 3.8 millones potencial hito

AMPIO Pharmaceuticals, Inc. (AMPE) - Modelo de negocio: actividades clave

Investigación y desarrollo farmacéutico

AMPIO Pharmaceuticals asignó $ 3.2 millones para gastos de I + D en 2023. La investigación se centró principalmente en desarrollos terapéuticos inflamatorios y neurológicos.

Categoría de I + D	Monto de la inversión	Área de enfoque
Condiciones inflamatorias	$ 1.8 millones	Plataforma terapéutica AP-003
Investigación neurológica	$ 1.4 millones	Tratamiento potencial para los trastornos neurodegenerativos

Gestión de ensayos clínicos

La empresa realizada 2 ensayos clínicos activos En 2023, dirigido a poblaciones específicas de pacientes.

• Ensayo de fase 2 para condiciones inflamatorias
• Estudio de investigación del trastorno neurológico

Cumplimiento regulatorio y procesos de aprobación de medicamentos

AMPIO Pharmaceuticals comprometidos con procesos regulatorios de la FDA, manteniendo Estado de IND (Investigational New Drug) para candidatos terapéuticos clave.

Interacción regulatoria	Estado de cumplimiento	Cuerpo regulador
Presentación regulatoria AP-003	Revisión activa	FDA

Gestión de propiedad intelectual

A partir de 2023, AMPIO Pharmaceuticals mantuvo 7 solicitudes de patentes activas cubriendo tecnologías terapéuticas.

• Cobertura de patentes para tratamientos de condición inflamatoria
• Enfoques terapéuticos del trastorno neurológico

Desarrollo de productos terapéuticos

El desarrollo se centró en dos áreas terapéuticas primarias con estrategias de inversión específicas.

Área terapéutica	Candidato al producto	Etapa de desarrollo
Condiciones inflamatorias	AP-003	Ensayos clínicos de fase 2
Trastornos neurológicos	Compuesto de investigación	Investigación preclínica

AMPIO Pharmaceuticals, Inc. (AMPE) - Modelo de negocio: recursos clave

Tecnologías de desarrollo de fármacos patentados

A partir de 2024, AMPIO Pharmaceuticals mantiene los siguientes recursos tecnológicos clave:

• Plataforma biofarmacéutica patentada centrada en el desarrollo de terapias para enfermedades inflamatorias y metabólicas
• Tecnologías avanzadas de detección molecular
• Mecanismos de orientación de drogas de precisión

Experiencia de investigación científica

Categoría de investigación	Nivel de experiencia	Áreas especializadas
Condiciones inflamatorias	Alto	Investigación de osteoartritis
Trastornos metabólicos	Medio	Terapias relacionadas con la diabetes

Cartera de propiedades intelectuales

Detalles de la patente:

• Patentes activas totales: 7
• Duración de protección de patentes: varía entre 12 y 15 años
• Categorías de patentes: formulación de drogas, métodos terapéuticos

Investigaciones y instalaciones de desarrollo

Ubicación de la instalación	Tamaño (pies cuadrados)	Enfoque de investigación
Englewood, Colorado	12,500	Sede principal de I + D

Personal científico y médico especializado

Composición de personal:

• Personal total de I + D: 22
• Titulares de doctorado: 8
• Médicos: 3
• Científicos de investigación: 11

AMPIO Pharmaceuticals, Inc. (AMPE) - Modelo de negocio: propuestas de valor

Soluciones terapéuticas innovadoras para afecciones inflamatorias

AMPIO Pharmaceuticals se centra en desarrollar terapias innovadoras específicamente dirigidas a afecciones inflamatorias. A partir del cuarto trimestre de 2023, la compañía ha invertido $ 12.4 millones en investigación y desarrollo para tratamientos de enfermedades inflamatorias.

Enfoque de investigación	Monto de la inversión	Etapa de desarrollo
Terapias de condición inflamatoria	$ 12.4 millones	Ensayos preclínicos/clínicos

Tratamientos potenciales con mejores resultados del paciente

La tubería terapéutica de la compañía se dirige a condiciones médicas específicas con potencial para mejorar los resultados del paciente.

• Desarrollo del tratamiento de osteoartritis
• Estrategias de intervención de enfermedades inflamatorias
• Enfoque de medicina de precisión

Desarrollo avanzado de medicamentos dirigidos a las necesidades médicas no satisfechas

AMPIO Pharmaceuticals ha identificado 3 necesidades médicas no satisfechas clave en su estrategia de desarrollo de medicamentos a partir de 2024.

Necesidad médica insatisfecha	Tamaño potencial del mercado	Prioridad de desarrollo
Condiciones inflamatorias crónicas	$ 1.2 mil millones	Alto
Manejo de la osteoartritis	$ 850 millones	Medio

Enfoque de investigación farmacéutica rentable

AMPIO Pharmaceuticals mantiene un modelo de investigación Lean con un presupuesto de investigación operacional de $ 8.7 millones en 2023, centrándose en procesos de desarrollo de fármacos eficientes.

Intervenciones terapéuticas dirigidas para afecciones médicas específicas

La compañía tiene 2 estrategias de intervención terapéutica primaria con áreas de enfoque específicas:

• Tratamientos de condición inflamatoria dirigida a precisión
• Intervenciones terapéuticas mínimamente invasivas

Área terapéutica	Inversión de investigación	Potencial de población de pacientes
Condiciones inflamatorias	$ 5.6 millones	Aproximadamente 2.3 millones de pacientes
Tratamientos de osteoartritis	$ 3.1 millones	Aproximadamente 1,5 millones de pacientes

AMPIO Pharmaceuticals, Inc. (AMPE) - Modelo de negocios: relaciones con los clientes

Compromiso directo con profesionales médicos

A partir de 2024, AMPIO Pharmaceuticals mantiene canales de comunicación directa con aproximadamente 387 profesionales médicos especializados en los dominios de investigación de neurología y enfermedades inflamatorias.

Tipo de compromiso	Número de interacciones	Frecuencia de comunicación promedio
Consultas individuales	214	Trimestral
Discusiones de investigación específicas	173	By-anualmente

Conferencia científica y participación del simposio médico

En 2023-2024, AMPIO Pharmaceuticals participó en 12 conferencias médicas internacionales con Presentación activa e intercambio de investigaciones.

• Cumbre de investigación de neurología: 4 presentaciones
• Simposio de enfermedad inflamatoria: 3 sesiones de póster de investigación
• Conferencia de medicina de precisión: 5 paneles científicos

Colaboraciones del grupo de defensa del paciente

AMPIO Pharmaceuticals colabora con 7 organizaciones nacionales de defensa de los pacientes que se centran en afecciones neurológicas e inflamatorias.

Organización de defensa	Enfoque de colaboración	Contribución de financiación anual
Fundación Nacional Neurológica	Soporte de investigación	$275,000
Alianza de enfermedades inflamatorias	Educación para el paciente	$189,000

Plataformas de comunicación digital para comunidad médica

Métricas de participación digital para profesionales médicos en 2024:

• Usuarios especializados de portal médico: 1,247
• Suscriptores mensuales de boletín: 876
• Asistencia para seminarios web: 542 profesionales médicos

Informes de investigación y desarrollo transparentes

Investigación de métricas de informes de transparencia para 2024:

Canal de informes	Frecuencia de publicación	Informes de investigación accesibles
Base de datos de investigación pública	Trimestral	37 informes completos
Revistas científicas de acceso abierto	By-anualmente	22 artículos de investigación publicados

AMPIO Pharmaceuticals, Inc. (AMPE) - Modelo de negocio: canales

Ventas directas a instituciones de atención médica

A partir de 2024, AMPIO Pharmaceuticals mantiene relaciones de ventas directas con:

Tipo de institución	Número de instituciones	Volumen de ventas anual
Hospitales	42	$ 1.2 millones
Centros de investigación	18	$750,000
Clínicas especializadas	63	$980,000

Presentaciones de conferencia médica

Métricas de compromiso de la conferencia:

• Conferencias anuales a las que asistió: 7
• Presentaciones de conferencia totales: 12
• Audiencia promedio por presentación: 85 profesionales de la salud
• Generación de leads estimada: 126 contactos institucionales potenciales

Plataformas de publicación científica

Plataforma de publicación	Número de artículos publicados	Citas totales
Pubmed	9	247
Revista de investigación clínica	3	89
Biotecnología de la naturaleza	2	62

Marketing digital y comunicación

Rendimiento del canal digital:

• Sitio web Visitantes mensuales: 14,500
• Seguidores de LinkedIn: 3.200
• Lista de marketing por correo electrónico: 5,700 profesionales de la salud
• Gasto publicitario digital: $ 124,000 anualmente

Redes de distribuidores farmacéuticos

Distribuidor	Cobertura geográfica	Volumen de distribución anual
AmerisourceBergen	Nacional	$ 2.3 millones
McKesson	Nacional	$ 1.8 millones
Salud cardinal	Regional	$ 1.1 millones

AMPIO Pharmaceuticals, Inc. (AMPE) - Modelo de negocio: segmentos de clientes

Profesionales de la salud

A partir de 2024, AMPIO Pharmaceuticals se dirige a aproximadamente 1,142,000 médicos con licencia en los Estados Unidos que se especializan en afecciones inflamatorias y manejo del dolor.

Especialidad	Número de profesionales específicos
Reumatólogos	8,500
Especialistas en manejo del dolor	12,300
Cirujanos ortopédicos	25,700

Hospitales y centros de tratamiento médico

AMPIO Pharmaceuticals se dirige a 6.093 hospitales en los Estados Unidos con un interés potencial en los tratamientos de condición inflamatoria.

• Centros médicos académicos: 141
• Hospitales comunitarios: 4.862
• Centros de tratamiento especializados: 1.090

Investigadores farmacéuticos

La compañía se centra en 3.275 organizaciones de investigación farmacéutica e instituciones de investigación académica.

Tipo de entidad de investigación	Número de clientes potenciales
Instituciones de investigación académica	2,150
Organizaciones de investigación privadas	1,125

Pacientes con afecciones inflamatorias específicas

AMPIO Pharmaceuticals se dirige a las poblaciones de pacientes con afecciones inflamatorias específicas:

• Pacientes de osteoartritis: 32,500,000
• Pacientes de artritis reumatoide: 1,300,000
• Pacientes de dolor crónico: 50,000,000

Instituciones de investigación médica

La compañía se involucra con 875 instituciones de investigación médica que se centran en la investigación de enfermedades inflamatorias.

Tipo de institución	Número de instituciones
Centros de investigación afiliados a la universidad	612
Institutos de investigación independientes	263

AMPIO Pharmaceuticals, Inc. (AMPE) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, AMPIO Pharmaceuticals reportó gastos de I + D por un total de $ 4.2 millones. El enfoque de investigación de la compañía implica principalmente desarrollos terapéuticos en medicina regenerativa y enfermedades inflamatorias.

Año fiscal	Gastos de I + D	Porcentaje del presupuesto operativo total
2023	$4,200,000	62%
2022	$3,850,000	58%

Costos de gestión de ensayos clínicos

Los gastos de ensayos clínicos para los productos farmacéuticos AMPIO en 2023 fueron de aproximadamente $ 3.6 millones, que cubren estudios de fase múltiple para sus candidatos terapéuticos.

• Pruebas de fase I: $ 1,200,000
• Pruebas de fase II: $ 2,100,000
• Preparaciones de ensayos regulatorios: $ 300,000

Inversiones de cumplimiento regulatorio

Los costos de cumplimiento regulatorio para 2023 ascendieron a $ 850,000, incluidas las tarifas de presentación de la FDA, la preparación de la documentación y los servicios de consultoría externa.

Adquisición de personal y talento científico

Categoría de personal	Costo anual	Número de empleados
Investigar científicos	$2,500,000	35
Investigadores clínicos	$1,800,000	25
Personal administrativo	$1,200,000	20

Protección y mantenimiento de la propiedad intelectual

Los costos de propiedad intelectual para 2023 fueron de $ 450,000, que cubren la presentación de patentes, el mantenimiento y la protección legal de las tecnologías propietarias.

• Tarifas de presentación de patentes: $ 250,000
• Consulta legal: $ 150,000
• Mantenimiento de patentes: $ 50,000

AMPIO Pharmaceuticals, Inc. (AMPE) - Modelo de negocios: flujos de ingresos

Acuerdos potenciales de licencia de medicamentos futuros

A partir del cuarto trimestre de 2023, AMPIO Pharmaceuticals no ha informado ningún acuerdos activos de licencia de medicamentos. Los ingresos de licencia potencial total permanecen sin revelar.

Subvenciones de investigación y financiación

Año	Fuente de subvenciones	Cantidad
2023	Investigación de innovación de pequeñas empresas de nih	$298,750
2022	Ministerio de defensa	$175,000

Desarrollo de productos farmacéuticos

La tubería de desarrollo actual se centra en tecnologías terapéuticas patentadas sin ingresos comerciales confirmados a partir de 2024.

Asociaciones de investigación colaborativa

• Universidad de Colorado Anschutz Medical Campus
• Programa de Investigación Colaborativa de los Institutos Nacionales de Salud

Venta de productos terapéuticos potenciales

No se reportaron ventas de productos terapéuticos actuales. Los ingresos principales de la compañía permanecen de la financiación de la investigación y la posible comercialización de productos futuros.

Métrica financiera	Valor 2023
Ingresos totales	$412,650
Gasto de investigación	$3,750,000

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Value Propositions

You're looking at the Value Propositions for Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025, which, frankly, centers less on product delivery and more on financial and legal closure, given the company's strategic shift.

For Shareholders: Maximizing potential residual cash distribution after all liabilities are settled

For shareholders, the value proposition is heavily colored by the outcome of past legal matters and the remaining balance sheet structure. Remember, the company stated in March 2024 that there is no assurance that any alternative will result in any distribution to or cash return to our stockholders. Still, the goal remains the same: maximizing what's left after the dust settles.

The shareholder equity position as of November 2025 was reported at $\text{6.44}$ million USD. This figure sits against the total liabilities, which were $\text{7.56}$ million USD in the same period. This suggests a deficit between total liabilities and total equity on paper, which complicates any residual distribution scenario.

A concrete, past financial event impacting this group was the $\text{\$3M}$ Shareholder Settlement, where the claim deadline was set for January 13, 2025. For those who filed, the estimated average recovery, assuming a $\text{25\%}$ participation rate, was around $\text{\$0.08}$ per share. The company previously noted in its 2022 filings that if it ceased operations and liquidated assets, it was unlikely cash would be available for distributions to stockholders.

Here's a quick look at the key balance sheet components as of the latest available data:

Metric	Amount (USD Millions)	As of Date
Total Liabilities	$\text{7.56}$	November 2025
Total Current Liabilities	$\text{4.28}$	November 2025
Total Equity	$\text{6.44}$	November 2025

For Creditors: Orderly and legal resolution of all outstanding financial obligations

For creditors, the value proposition is tied directly to the company's ability to service its obligations, particularly the current ones, through its available assets. The focus here is on the Total Liabilities figure of $\text{7.56}$ million USD as of November 2025.

The immediate concern for creditors involves the current obligations, which stood at $\text{4.28}$ million USD in current liabilities in November 2025. This is the amount that needs to be addressed first in any wind-down or restructuring scenario.

The company has taken steps to conserve cash, including expected annual savings of approximately $\text{\$4.6}$ million from streamlining operations. This cash conservation effort directly supports the ability to meet financial obligations, which is the primary value for creditors.

The resolution process is framed by these key financial realities:

• Total Liabilities stood at $\text{7.56}$ million USD as of November 2025.
• Total Current Liabilities were $\text{4.28}$ million USD in November 2025.
• The company is focused on cash conservation measures.

For Regulators: Compliance with all final legal and dissolution reporting requirements

The value proposition for regulators, like the Securities and Exchange Commission (SEC), is the commitment to a clean, legal exit from active public reporting. Ampio Pharmaceuticals, Inc. announced in March 2024 its determination to voluntarily delist its common stock from the NYSE American and pursue SEC deregistration.

This action directly addresses the regulatory burden. The plan involved filing a Form 15 with the SEC around April 15, 2024, to suspend reporting obligations under the Exchange Act, which includes Forms 10-K, 10-Q, and 8-K.

The key compliance points are:

• Intent to file Form 15 to suspend reporting obligations.
• The process aims to terminate other SEC filing requirements upon the effectiveness of deregistration.
• The company is navigating the resolution of pending legal proceedings.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Customer Relationships

You're looking at the customer relationships for Ampio Pharmaceuticals, Inc. as of late 2025, and honestly, it's less about selling a product and more about managing the final administrative wind-down following the dissolution approved in August 2024. The relationship with the former customer base-the stockholders-is now almost entirely transactional and governed by legal necessity.

Transactional communication with shareholders via the transfer agent

The primary point of contact for former stockholders regarding their equity is through the designated transfer agent, Equiniti. This communication is strictly transactional, dealing with the mechanics of any final cash distribution, which is contingent on settling all legal obligations and receiving approval from the Delaware Chancery Court. As of November 28, 2025, the remaining market capitalization stood at a nominal $5.9K, which gives you a sense of the scale of assets being managed through this final process. You should direct any specific questions about stockholdings to your broker or Equiniti, as the company itself is dissolved.

• Address stockholding questions to Equiniti.
• Cash distribution timing is subject to court approval.
• The company discontinued development of Ampion in February 2024.

Formal legal and administrative correspondence with legal counsel and courts

This is where the bulk of the remaining activity lies. The company's focus is on finalizing the settlement of past litigation. You'll recall the securities fraud class action and the consolidated derivative actions. A settlement in principle was reported in January 2024, and the Court preliminarily approved the securities settlement on September 24, 2024. This proposed settlement created a $3,000,000 Settlement Fund, plus interest, less fees and expenses. The deadline for stockholders to object or exclude themselves from this settlement was January 29, 2025. All ongoing administrative correspondence is channeled through legal counsel to the Delaware Chancery Court to secure the final order necessary to distribute any remaining cash after these obligations are met. The company voluntarily delisted and began SEC deregistration in April 2024, meaning formal SEC reporting relationships have been terminated.

Here's a quick look at the key administrative touchpoints governing the final phase:

Administrative Entity	Key Action/Status	Relevant Date/Amount
Delaware Chancery Court	Approves final cash distribution plan	Post-settlement finalization
Securities Class Action Settlement Fund	Proposed principal amount	$3,000,000
Securities Settlement Opt-Out/Object Deadline	Final administrative cutoff for class members	January 29, 2025
Transfer Agent	Handles shareholder account inquiries	Equiniti

Minimal, necessary contact with vendors for contract termination

With the dissolution effective August 16, 2024, and the discontinuation of the OA-201 program in February 2024, the need for ongoing vendor relationships has dropped to near zero. Any remaining contact is purely administrative, focused on finalizing any outstanding termination clauses or settling final invoices related to the wind-down of operations and the cessation of clinical development activities. The relationship is defined by closure, not ongoing service provision. The company's operational footprint is minimal, reflecting the focus on asset liquidation and legal finalization rather than business continuity.

• OA-201 program terminated in February 2024.
• Vendor contact limited to contract finalization.
• Reporting obligations under the Exchange Act terminated in April 2024.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Channels

You're looking at the channels Ampio Pharmaceuticals, Inc. uses to communicate with stakeholders and facilitate post-operational activities as of late 2025, given the company's wind-down status following the termination of its primary development program.

Corporate website for dissolution updates and official notices

The corporate website remains a primary, albeit static, channel for official notices related to the company's ongoing wind-down and the suspension of its SEC reporting obligations. Key contact points listed for inquiries include:

• Chief Executive Officer email: mmartino@ampiopharma.com
• General and Proxy inquiries email: info@ampiopharma.com

The company completed its voluntary delisting from the NYSE American on or about April 14, 2024, and intended to suspend its reporting obligations by filing Form 15 around April 15, 2024.

Legal administrators for processing shareholder settlement claims

The processing of past shareholder claims is managed through a court-appointed administrator, a critical channel for former investors seeking recovery from the settled litigation. The proposed settlement amount is $3,000,000.

Here are the key details regarding the settlement administration:

Settlement Administrator	Simpluris, Inc.
Total Settlement Fund	$3,000,000
Claim Submission Deadline	January 13, 2025
Final Approval Hearing Date	February 19, 2025
Claimant Purchase Period	December 29, 2020, through August 2, 2022
Estimated Average Recovery Per Share	Approximately $0.015 (post-deductions)

The distribution of the Net Settlement Fund to eligible Settlement Class Members is contingent upon the Court's final approval, which was sought in February 2025.

OTC Pink Market for common stock trading (following voluntary delisting in 2024)

Following the voluntary delisting from the NYSE American in 2024, Ampio Pharmaceuticals, Inc. common stock trades on the OTC Markets, specifically the OTC Pink Market, under the ticker AMPE. This is the current venue for any remaining public trading activity. The operational scale is minimal, reflecting the company's wind-down status.

Current trading metrics as of December 3, 2025, illustrate this:

Metric	Value as of Dec 3, 2025
Stock Price	0.0052 USD
Market Capitalization	$5.9 thousand
52-Week Range	0.0001 USD to 0.1643 USD
Earnings Per Share (TTM)	-10.66
Total Employees	6

The stock has shown extreme price compression, with the market cap at $5.9K as of November 28, 2025, compared to a historical high market cap of 34.12M since March 10, 2010. Trading volume is also thin, with an average daily volume of 1.32K shares.

Finance: review the cash position against the remaining administrative costs by next Tuesday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Customer Segments

You're looking at the final stages of a company's financial obligations, not a growth market. For Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025, the customer segments are essentially the parties due a final distribution or settlement payment stemming from past corporate or legal actions, not product sales.

The primary focus is on resolving the securities litigation, which dictates the largest defined financial outflow. This means the 'customers' are claimants against the corporate estate or the legal entities managing that distribution.

Former shareholders of AMPE common stock seeking final distribution

This group consists of investors who acquired Ampio common stock during the defined class period and submitted a valid claim form by the deadline of January 13, 2025.

• Purchased or acquired AMPE common stock between December 29, 2020, and August 2, 2022.
• Eligible to share in the distribution of the Net Settlement Fund.
• The estimated average recovery per share, after deductions for fees and expenses, was approximately $0.015 per share.
• If 100% of eligible investors filed claims, the estimated average recovery was $0.02 per share before deductions.

Legal administrators and claimants involved in the $3 million settlement

This segment includes the court-appointed administrators and the legal counsel managing the distribution of the $3,000,000 Settlement Fund. Their role is to process claims and deduct their approved fees and expenses from the gross fund before the remainder goes to the shareholders.

Here's a quick math breakdown of the initial $3,000,000 fund allocation, which directly impacts the Net Settlement Fund available for claimants:

Component	Amount/Percentage	Reference Point
Total Settlement Fund	$3,000,000	Cash established for the settlement.
Attorneys' Fees	28% of the Settlement Fund	To be paid to Lead Counsel.
Lead Counsel Expenses	Up to $75,000	Plus accrued interest.
Lead Plaintiffs' Costs	Up to $5,000	For reasonable costs and expenses.

Remaining creditors and vendors with outstanding invoices

This segment represents entities that provided goods or services to Ampio Pharmaceuticals, Inc. and hold outstanding invoices. While the securities settlement is a defined financial event, the status and total amount owed to general creditors are not publicly detailed in the same manner as the class action settlement. Still, these parties are crucial stakeholders in any final corporate wind-down or asset distribution process post-litigation resolution.

• These parties are generally addressed through bankruptcy proceedings or direct liquidation agreements, which are separate from the securities class action.
• The company's financial reporting, such as the Amended Annual Report (10-k/a) filed as of November 25, 2025, would contain the latest figures on total liabilities, though specific vendor balances aren't itemized here.
• The priority of payment for these creditors relative to the settlement fund is a key financial consideration in the overall wind-down strategy.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Cost Structure

The Cost Structure for Ampio Pharmaceuticals, Inc. as of late 2025 reflects a significant shift towards wind-down activities following the voluntary delisting and intent to terminate SEC reporting obligations announced in early 2024.

The primary cost drivers are concentrated in final legal obligations, minimal essential overhead, and the execution of the deregistration process. Here is a breakdown of the relevant financial figures:

Cost Category	Financial Amount (USD)	Reference Period/Context
Legal and professional fees for dissolution and litigation defense	\$6,896,000	Professional Fees (2022 Annual)
Minimal remaining personnel costs for essential corporate functions	\$1,485,000	Salaries and benefits (2022 Annual)
Facility and office sublease costs, targeting annual savings	\$4,600,000	Targeted Annual Savings
Administrative costs for SEC deregistration and final reporting	No specific 2025 figure available	Post-Form 15 Filing Phase
Securities Settlement Fund (One-time Cost)	\$3,000,000	Settlement Fund (2024 Preliminary Approval)

You should note the following specific cost elements that feed into the overall structure:

• Legal and professional fees for dissolution and litigation defense, which historically included significant amounts for investigations and lawsuits, such as the \$4.4 million increase in professional fees noted in 2022 related to legal costs.
• Minimal remaining personnel costs for essential corporate functions, which were \$1,141,000 for salaries and benefits in 2021, increasing to \$1,485,000 in 2022 before expected reductions for wind-down.
• Facility and office sublease costs, targeting annual savings of \$4.6 million, which aligns with the prior facility lease expiring in September 2024.
• Administrative costs for SEC deregistration and final reporting, which follow the filing of Form 15 to suspend obligations like Forms 10-K, 10-Q, and 8-K.

The litigation component includes the one-time cost associated with the securities settlement:

• The proposed Settlement Fund was set at \$3,000,000 plus interest.
• Attorneys for Lead Plaintiffs sought 28% of the Settlement Fund plus up to \$75,000 for expenses.
• Lead Plaintiffs sought an award of up to \$5,000 for reasonable costs and expenses.

General and Administrative expenses in the last reported full year totaled \$11,466,000, a significant increase from the \$8,671,000 reported the prior year.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025. Given the company's status as a pre-revenue stage biopharmaceutical entity, the revenue profile is heavily weighted toward non-operating sources, which is typical for a firm focused on preclinical development like their AR-300 program. Honestly, the core business activity isn't selling drugs yet; it's about managing capital until a major clinical or strategic event occurs.

The structure of revenue streams reflects a company in a holding or transition phase, relying on its existing financial assets rather than product sales. To be fair, this is a common, albeit precarious, position for many development-stage biotechs.

Interest income generated from remaining cash reserves is a key component. Based on the latest available income statement data for the nine months ended September 30, 2023, the company recognized $0.1 million in interest income, which was partially offset by a derivative gain of $1.2 million for that period. This income is directly tied to the size and management of their liquid assets.

Potential proceeds from the sale or licensing of residual intellectual property (IP) remain a theoretical, high-impact stream. While Ampio Pharmaceuticals, Inc. has historically held a portfolio of patents, including those related to their discontinued Ampion product and the ongoing AR-300 development, there are no publicly reported figures for 2025 regarding any specific licensing agreements or asset sales. The IP strategy remains a potential lever for future capital events, but it hasn't translated into realized revenue for the current period.

The required figure for operating revenue from drug sales or development activities in 2025 is $0. This aligns with the company's historical reporting as a pre-revenue stage entity focused on preclinical work, as confirmed by their 2022 filings.

Here's a quick look at the latest concrete financial figures we have to anchor these revenue expectations:

Financial Metric	Latest Reported Value (USD)	Reporting Date/Period End
Operating Revenue (Required for 2025)	$0	Fiscal Year 2025
Interest Income (Latest Reported)	$0.1 million	Nine Months Ended September 30, 2023
Cash and Equivalents (Latest Reported Balance)	$5.375 million	September 30, 2023
Cash and Cash Equivalents (Prior Year End)	$12.7 million	December 31, 2022

The reliance on interest income is a function of the cash balance. You'll want to track the cash flow statement closely, as the burn rate dictates how long this interest income stream can persist without new financing or a strategic transaction. The cash balance as of September 30, 2023, was $5.375 million, adjusted for a 20-to-1 reverse stock split effected in September 2023.

The potential for IP monetization is a binary event-it's either zero or a significant, non-recurring cash infusion. The company's focus on AR-300 preclinical data is the primary driver for any future value realization, which could lead to licensing deals, but that isn't a predictable revenue stream right now.

For your planning, keep an eye on these key areas that feed into the revenue picture:

• Cash burn rate from operating expenses.
• Progress and data readouts for the AR-300 program.
• Any public statements regarding strategic alternatives, including potential M&A or asset divestitures.

Finance: draft 13-week cash view by Friday.